You are here

UK pharma sector stays immune to Brexit as innovation, scale spur deals

Sector being propelled in part by weaker pound and need to keep pipelines supplied with new, lucrative treatments


AS the United Kingdom's vote to leave the European Union wreaks havoc on the British economy, dealmaking momentum in the country's pharmaceutical industry is showing no signs of letting up.

Healthcare acquisitions in the UK have risen 21 per cent this year as total mergers